Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years

Pfizer/BioNTech Announce Positive Results for Third Dose of its COVID-19 Childhood Vaccine

Grant Paulsen, MD, assistant professor, Division of Infectious Diseases, Division of Pediatrics, Cincinnati Children’s Hospital Medical Center in Ohio, and principal investigator for the hospital’s clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19 , discusses what the data could mean for children ages 5 to 11.

Comments are closed.